Evidence map›Paper›PMID 37280350›Full record

ReviewEye (London, England)2023

Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries.

Anat Loewenstein, Alan Berger, Avril Daly, Catherine Creuzot-Garcher, Richard Gale, Federico Ricci, Javier Zarranz-Ventura, Robyn Guymer

Erratum issuedAbstract readReview
In one paragraph

Review in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Anat LoewensteinOphthalmology Division, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel. anatl@tlvmc.gov.il.ORCID 0000-0002-7706-1165
Alan BergerSt. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Avril DalyRetina International, Dublin, Ireland.
Catherine Creuzot-GarcherDijon University Hospital, Dijon, France.
Richard GaleHull York Medical School, University of York, York, UK.
Federico RicciDept. Experimental Medicine - University Tor Vergata of Rome, Rome, Italy.
Javier Zarranz-VenturaHospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-2338-8143
Robyn GuymerCentre for Eye Research, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-9441-4356

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With a growing aging population, the prevalence of age-related eye disease and associated eye care is expected to increase. The anticipated growth in demand, coupled with recent medical advances that have transformed eye care for people living with retinal diseases, particularly neovascular age-related macular degeneration (nAMD) and diabetic eye disease, has presented an opportunity for health systems to proactively manage the expected burden of these diseases. To do so, we must take collective action to address existing and anticipated capacity limitations by designing and implementing sustainable strategies that enable health systems to provide an optimal standard of care. Sufficient capacity will enable us to streamline and personalize the patient experience, reduce treatment burden, enable more equitable access to care and ensure optimal health outcomes. Through a multi-modal approach that gathered unbiased perspectives from clinical experts and patient advocates from eight high-income countries, substantiated perspectives with evidence from the published literature and validated findings with the broader eye care community, we have exposed capacity challenges that are motivating the community to take action and advocate for change. Herein, we propose a collective call-to-action for the future management of retinal diseases and potential strategies to achieve better health outcomes for individuals at-risk of, or living with, retinal disease.

Indexed as

AgingRetinal DiseasesAgedDeveloped CountriesHumans

Identifiers

PMID37280350
PMCPMC10630379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.